Long Circulating liposomes: Challenges and Opportunities

Abstract

The poor pharmacokinetic parameters and low solubility of many anticancer therapeutics have warranted the use of drug-delivery systems such as liposomes. Overcoming some drawbacks of the conventional liposomes, targeted liposomal delivery by longer circulation time by addition of poly(ethylene glycol) to the liposomal surface and further adding specific ligands to achieve ligand selective retention and uptake has been introduced. PEGylated liposomes are the only second-generation liposomal formulations in clinical use and are now being challenged with the allergenic response they pose even in the treatment of naive patients. This article will review the challenges and hindrances in the use of long circulating liposomes and explore the opportunities to overcome this issue.

Effect of hydrophobically modified PEO polymers (PEO-dodecyl) on oil/water microemulsion properties: in vitro and in silico investigations

“…These polymers prolong the blood circulation time of the microemulsions, just like liposomes. [50][51][52] Thus, the accumulation of drugs could be signicantly improved, within the target diseased sites, with the presence of polymers. Thus, the covered nanovesicles enhance the effect of permeation and retention.…”

Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications

“…Although reducing the in vivo drugs toxicity, being recognized as foreign substances by serum opsonines and destroyed by the reticuloendothelial system (RES), conventional liposomes are characterized by a short circulation time when intravenously administered [17,35].…”

Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis

“…Additionally, liposomes face several biological challenges for drug delivery. This includes preferential uptake by the reticuloendothelial system (RES) and opsonization (Poste et al, 1976;Senior, 1986), high clearance of large liposomes (Oku and Namba, 1994;Ulrich, 2002), the "accelerated blood clearance" (ABC) phenomenon if PEGylated liposomes are administered repeatedly (Ishida et al, 2006;Dams et al, 2000), and potential triggering of the innate immune response (Szebeni, 2005;Szebeni and Moghimi, 2009). While the unique anatomy and physiology of the lungs could attenuate some of these concerns, they should still be kept in mind when designing a liposome aerosol.…”